Current Approach to Heart Failure
Editat de Maria Dorobanţu, Frank Ruschitzka, Marco Metraen Limba Engleză Hardback – 20 ian 2017
The topic of heart failure is continuously changing, with new important information being added constantly. The pathophysiology is better understood and there is a trend for a better characterization of special groups of population, such as oncologic patients with heart failure. The new imaging techniques have become valuable tools for the diagnosis of heart failure, while pharmacological and novel cell and gene treatments have evolved enormously.
The challenge for the practitioners is making the right selection of treatment strategy that best fits a patient. This book presents detailed information on the indications, selection and mechanism of action of these treatments, whether they be mechanical circulatory devices or pharmacological treatments. The contemporary pharmacological and non-pharmacological management of heart failure has the main target of early prevention of disease progression and the avoidance of heart transplant. In the era of shortage of donors, prevention is the mainstay of the therapeutic strategy, and this is the main philosophy of our book.
| Toate formatele și edițiile | Preț | Express |
|---|---|---|
| Paperback (1) | 991.31 lei 39-44 zile | |
| Springer International Publishing – 17 iul 2018 | 991.31 lei 39-44 zile | |
| Hardback (1) | 1088.34 lei 39-44 zile | |
| Springer International Publishing – 20 ian 2017 | 1088.34 lei 39-44 zile |
Preț: 1088.34 lei
Preț vechi: 1145.61 lei
-5% Nou
Puncte Express: 1633
Preț estimativ în valută:
208.32€ • 218.69$ • 172.09£
208.32€ • 218.69$ • 172.09£
Carte tipărită la comandă
Livrare economică 27 ianuarie-01 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319452364
ISBN-10: 3319452363
Pagini: 696
Ilustrații: IX, 642 p. 110 illus., 30 illus. in color.
Dimensiuni: 155 x 235 x 38 mm
Greutate: 1.38 kg
Ediția:1st ed. 2016
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3319452363
Pagini: 696
Ilustrații: IX, 642 p. 110 illus., 30 illus. in color.
Dimensiuni: 155 x 235 x 38 mm
Greutate: 1.38 kg
Ediția:1st ed. 2016
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
V-ar putea interesa
-
Atlas of Cardiovascular Pathology for the ClinicianBruce M. McManus-5%Preț: 1127.23 lei1186.55 lei -
Atlas of EchocardiographyScott D. Solomon-5%Preț: 1578.53 lei1661.60 lei -
State-of-the-Art Imaging in StrokeB. Schaller-27%Preț: 1208.15 lei1652.33 lei -
Angiotensin Research ProgressHina Miura-27%Preț: 1109.86 lei1521.92 lei -
Optimization of Paced AV Delay Using Atrial Contribution IndexMiroslav Mestan-27%Preț: 285.64 lei391.31 lei -
Coronary Circulation in NonsmoAurelio Leone-27%Preț: 744.59 lei1016.79 lei -
Angina PectorisAlice Gallo-27%Preț: 1111.49 lei1522.90 lei -
Bacterial EndocarditisClaudia L. Dominguez-27%Preț: 836.83 lei1148.91 lei -
-27%Preț: 748.91 lei1019.42 lei -
Psychological Factors and Cardiovascular DisordersLeo, M.D. Sher-26%Preț: 562.81 lei758.42 lei -
Computed Tomography of the Coronary ArteriesPim J. de Feyter-17%Preț: 831.13 lei1000.50 lei -
Foam Sclerotherapy: A TextbookJohn J. Bergan-18%Preț: 1062.39 lei1294.52 lei -
Protocols and Methodologies in Basic Science and Clinical Cardiac MRIChristakis Constantinides-5%Preț: 935.85 lei985.11 lei -
-5%Preț: 666.67 lei701.76 lei -
Hypertension and Cardiac Organ DamageRaffaele Izzo-5%Preț: 349.67 lei368.08 lei -
Hypertension and Renal Organ DamageRoberto Pontremoli-5%Preț: 349.67 lei368.08 lei -
Cardiovascular Surgery: A Clinical CasebookRui Manuel de Sousa Sequeira Antunes de Almeida-18%Preț: 712.40 lei868.78 lei -
Atlas of Pediatric and Youth ECGGabriele Bronzetti-5%Preț: 838.14 lei882.25 lei -
Practical Manual of Tricuspid Valve DiseasesOsama I. Soliman-5%Preț: 712.37 lei749.87 lei -
-5%Preț: 509.59 lei536.40 lei -
Cancer and Cardiovascular Disease: A Concise Clinical AtlasSyed Wamique Yusuf-5%Preț: 1172.98 lei1234.72 lei -
Essentials of Hypertension: The 120/80 paradigmFlávio Danni Fuchs-5%Preț: 590.65 lei621.74 lei
Cuprins
Evolving concepts on the basic mechanisms of heart failure.- Assessment of left ventricular systolic and diastolic dysfunction.- Right ventricular dysfunction in heart failure.- The role of atrial functional assessment in heart failure.- Assessment of secondary mitral regurgitation.- Assessment of left ventricular contractile reserve in heart failure.- Role of cardiac magnetic resonance imaging in heart failure.- The evolving role of multimodality imaging in heart failure.- Contemporary pharmacological treatment of heart failure.- Myocardial revascularization in heart failure.- Approach to arrhythmia in heart failure.- Implantable defibrillator therapy.- Cardiac resynchronization therapy.- Mechanical circulatory support.- Cell and gene therapy in heart failure.- Valvular Surgery in Heart Failure.- Percutaneous Valvular Therapies in Heart Failure.- Pretransplant evaluation.- Strategies for improving outcomes in heart transplantation.- Heart failure and hypertension.- Right heart failure.- Acute heart failure.- Heart failure in oncologic patients.- Iron Deficiency in Heart Failure.- The kidney and electrolyte imbalances in heart failure.- Prognostic factors and risk scores in heart failure.- Rehabilitation therapy in patients with heart failure.
Recenzii
“Current Approach to Heart Failure is a 642-page book that addresses a very important and rapidly evolving clinical problem. … The book is well written, referenced, and up to date. … this book is extremely relevant for any clinician working with patients with heart failure. It provides useful information, includes well-summarized, state-of-the-art concepts, and is a valuable resource to have.” (André Y. Denault and Geneviève Giraldeau, Anesthesia & Analgesia, Vol. 125 (4), October, 2017)
Notă biografică
Prof Maria Dorobanţu is professor of Cardiology at the University of Medicine and Pharmacy Carol Davila Bucharest, Romania, and head of the Cardiology Department of Clinical Emergency Hospital, Bucharest. She has a special interest in the assessment and treatment of acute heart failure (HF). She has been principal investigator in the the phase III RELAX-AHF and RELAX-AHF-2 trials as well as SENIORS and BEAUTIFUL trials. These trials regard the effects of the new agent serelaxin in the patients with acute HF. Between 2008 and 2014 she was member of CPC of ESC, Group of Hypertension.
Prof Marco Metra is professor of cardiology at the University of Brescia and directs the Institute of Cardiology of the University and Civil Hospital of Brescia, Italy. Prof Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with HF. His research is focused on HF: β-blocker therapy, cardiopulmonary exercise testing andthe assessment and treatment of acute HF. Prof Metra is also member of the Executive Committee or data Monitoring Committee of many major trials regarding the treatment of HF. As board member of the HF Association (HFA) of the European Society of Cardiology (ESC) from 2001 to 2008, He has been a member of the ESC’s Committee for Practice Guidelines (years 2004–8), and has been co-chair of the 2008 meeting of the HFA of ESC, held in Milan in June 2008.
Prof Frank Ruschitzka is head of the HF and Transplantation Clinic at the University Hospital in Zürich, Switzerland. He specialized in internal medicine, nephrology and cardiology at the Universities of Göttingen and Zürich. In 2003, he was awarded the annual Götz-Preis of the Medical Faculty of the University of Zürich for excellence in clinical medicine and research. He is the President Elect of the HF Association of the ESC. Professor Ruschitzka's research interests focusses on delineating novel targets and therapies in coronary artery disease and HF.
Prof Marco Metra is professor of cardiology at the University of Brescia and directs the Institute of Cardiology of the University and Civil Hospital of Brescia, Italy. Prof Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with HF. His research is focused on HF: β-blocker therapy, cardiopulmonary exercise testing andthe assessment and treatment of acute HF. Prof Metra is also member of the Executive Committee or data Monitoring Committee of many major trials regarding the treatment of HF. As board member of the HF Association (HFA) of the European Society of Cardiology (ESC) from 2001 to 2008, He has been a member of the ESC’s Committee for Practice Guidelines (years 2004–8), and has been co-chair of the 2008 meeting of the HFA of ESC, held in Milan in June 2008.
Prof Frank Ruschitzka is head of the HF and Transplantation Clinic at the University Hospital in Zürich, Switzerland. He specialized in internal medicine, nephrology and cardiology at the Universities of Göttingen and Zürich. In 2003, he was awarded the annual Götz-Preis of the Medical Faculty of the University of Zürich for excellence in clinical medicine and research. He is the President Elect of the HF Association of the ESC. Professor Ruschitzka's research interests focusses on delineating novel targets and therapies in coronary artery disease and HF.
Textul de pe ultima copertă
This book is intended to be a link between guidelines and clinical practice, a complementary tool to help physicians to be well informed regarding the important field of heart failure. It will be a useful tool for professionals from all the fields of cardiology: non-invasive cardiology, interventional cardiology, electrophysiology and cardiovascular imaging.
The topic of heart failure is continuously changing, with new important information being added constantly. The pathophysiology is better understood and there is a trend for a better characterization of special groups of population, such as oncologic patients with heart failure. The new imaging techniques have become valuable tools for the diagnosis of heart failure, while pharmacological and novel cell and gene treatments have evolved enormously.
The challenge for the practitioners is making the right selection of treatment strategy that best fits a patient. This book presents detailed information on the indications, selection and mechanism of action of these treatments, whether they be mechanical circulatory devices or pharmacological treatments. The contemporary pharmacological and non-pharmacological management of heart failure has the main target of early prevention of disease progression and the avoidance of heart transplant. In the era of shortage of donors, prevention is the mainstay of the therapeutic strategy, and this is the main philosophy of our book.
The topic of heart failure is continuously changing, with new important information being added constantly. The pathophysiology is better understood and there is a trend for a better characterization of special groups of population, such as oncologic patients with heart failure. The new imaging techniques have become valuable tools for the diagnosis of heart failure, while pharmacological and novel cell and gene treatments have evolved enormously.
The challenge for the practitioners is making the right selection of treatment strategy that best fits a patient. This book presents detailed information on the indications, selection and mechanism of action of these treatments, whether they be mechanical circulatory devices or pharmacological treatments. The contemporary pharmacological and non-pharmacological management of heart failure has the main target of early prevention of disease progression and the avoidance of heart transplant. In the era of shortage of donors, prevention is the mainstay of the therapeutic strategy, and this is the main philosophy of our book.
Caracteristici
Practical in its approach, this book addresses heart failure in both special populations and other frequent situations in clinical practice Includes material dedicated to cell and gene therapy in heart failure Presents the practical aspects of heart failure as a combination of experiential and evidence-based medicine Addresses the interdisciplinary approach to heart failure with chapters on anemia, kidney disease or electrolyte imbalances in heart failure